Tyrosine kinase and bosutinib complex. Computer illustration showing a molecule of bosutinib (spheres) bound to a tyrosine kinase molecule (grey). Tyr
Tyrosine kinase and bosutinib complex. Computer illustration showing a molecule of bosutinib (spheres) bound to a tyrosine kinase molecule (grey). Tyrosine kinase is an enzyme that can transfer a phosphate group from ATP (adenosine triphosphate) to a protein in a cell. Bosutinib is a Bcr-Abl tyrosine-kinase inhibitor (TKI), a group of TKIs that inhibit tyrosine kinase associated with the Philadelphia chromosome (Bcr-Abl). Bcr-Abl TKIs are the first-line therapy for most patients with chronic myelogenous leukaemia (CML). Over 90 percent of CML cases are caused by a chromosomal abnormality that results in the formation of a so-called Philadelphia chromosome.
Size: 4334px × 6128px
Photo credit: © RAMON ANDRADE 3DCIENCIA/SCIENCE PHOTO LIBRARY / Alamy / Afripics
License: Licensed
Model Released: No
Keywords: -, background, bcr-abl, biochemical, biochemistry, biological, biology, bosutinib, cancer, cell, chemical, chemistry, chromosome, chronic, cml, cytological, cytology, drug, drugs, enzyme, inhibitor, kinase, leukaemia, leukemia, model, molecular, molecule, myelogenous, oncological, oncology, pharmacological, pharmacology, philadelphia, protein, proteins, proteomics, quaternary, structural, structure, structures, tki, treatment, tyrosine, tyrosine-kinase, white
